Bora Capital

Research

Research.

Short notes from selected BORA research work. These are not current recommendations.

No assurance any analysis remains current.

01

Research date

July 2025

China E-commerce

Alibaba, JD.com, Pinduoduo

A basket bet on dominant Chinese e-commerce platforms trading at low earnings multiples.

The work depends on durability, regulation, and whether low multiples compensate for China-specific risk.

Alibaba

10.8x

JD.com

5x

Pinduoduo

7.2x

02

Research date

July 2025

British American Tobacco

British American Tobacco

A cash-flow case: a declining but resilient cigarette business funding reduced-risk products.

Tobacco remains exposed to regulation, litigation, taxes, and category decline.

Adjusted P/E

13x

Dividend yield

8%

Cigarettes sold

500B+

03

Research date

August 2025

Health Insurance

UnitedHealth, Centene, Molina

A basket of large health insurers where earnings power had to be weighed against policy pressure.

Medical-cost trend, reimbursement changes, and regulation can change the economics quickly.

UnitedHealth

10.8x

Centene

7x

Molina

8.5x

04

Research date

April 2025

Japanese Sogo Shosha

Itochu, Marubeni, Mitsubishi, Mitsui, Sumitomo

A basket of diversified Japanese trading companies with long operating histories and shareholder payouts.

The question is whether complexity, currency, and commodity exposure are being over-discounted.

Itochu

11-13x

Mitsubishi

9-10x

Sumitomo

8-9x

05

Research date

2025

Offshore Drilling

Valaris, Noble Corp.

A replacement-cost case where market value was compared with the cost to rebuild offshore drilling fleets.

The case depends on supply discipline and contract economics turning asset value into cash flow.

Valaris EV

~$3.4B

Fleet build cost

~$13.4B

New drillship

~$1B

06

Research date

2025

Burford and Legal Finance

Burford Capital

A legal-finance case where reported earnings can miss asset-by-asset value creation.

Legal timing, appeals, collection risk, and lumpy realizations make the economics hard to screen.

Litigation finance

Largest cited

Management stake

10%

Adjusted P/E

7-8x

Research is for informational purposes only and is not individualized investment advice or a recommendation to buy or sell any security. Examples are general in nature and may not be suitable for any particular person. Investing involves risk, including possible loss of principal.

Full Disclosures